Eli Lilly soldiers on in big PhIII evacetrapib study

Eli Lilly ($LLY) says that it will push ahead to the end on its Phase III study of evacetrapib, a CETP inhibitor that hopes to succeed where other giants have failed. Lilly says that the ACCELERATE study data monitoring committee recommended continuing the study following a futility analysis. The last patient visit in the study is expected in July of 2016. Investigators recruited roughly 12,000 patients for this trial. Release

Suggested Articles

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Broad Institute researchers showed that base-editing the Tmc1 gene preserved hair cells that helped transmit sound in the ears of mice.